The observed disparity in median survival times between high‐expression and low‐expression cohorts not only highlights CDKN2A's prognostic relevance but also showcases the potential clinical usefulness of the GBM model, as reflected by its predictive effectiveness with an AUC of 0.806 in the training set. Here, CDKN2A is linked to glioblastoma.